MX2007005827A - S-mirtazapina para el tratamiento del sofoco. - Google Patents
S-mirtazapina para el tratamiento del sofoco.Info
- Publication number
- MX2007005827A MX2007005827A MX2007005827A MX2007005827A MX2007005827A MX 2007005827 A MX2007005827 A MX 2007005827A MX 2007005827 A MX2007005827 A MX 2007005827A MX 2007005827 A MX2007005827 A MX 2007005827A MX 2007005827 A MX2007005827 A MX 2007005827A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mirtazapine
- week
- rats
- day
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 69
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 title claims abstract description 33
- 206010060800 Hot flush Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 12
- 208000033830 Hot Flashes Diseases 0.000 claims description 22
- 229960001785 mirtazapine Drugs 0.000 claims description 21
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 20
- 206010003497 Asphyxia Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 43
- 241000700159 Rattus Species 0.000 description 41
- 230000001457 vasomotor Effects 0.000 description 40
- 230000000694 effects Effects 0.000 description 29
- 230000006742 locomotor activity Effects 0.000 description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 15
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 206010016334 Feeling hot Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009329 sexual behaviour Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016275 Fear Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- RPUBHMMISKEXSR-BTJKTKAUSA-N mirtazapine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RPUBHMMISKEXSR-BTJKTKAUSA-N 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229940123486 Hormone receptor agonist Drugs 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 239000000698 hormone receptor stimulating agent Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000037211 monthly cycles Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- -1 salt maleate Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105778 | 2004-11-15 | ||
| PCT/EP2005/055947 WO2006051111A1 (en) | 2004-11-15 | 2005-11-14 | S-mirtazapine for the treatment of hot flush |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007005827A true MX2007005827A (es) | 2007-07-20 |
Family
ID=34929859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007005827A MX2007005827A (es) | 2004-11-15 | 2005-11-14 | S-mirtazapina para el tratamiento del sofoco. |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20070265245A1 (enExample) |
| EP (1) | EP1814555B1 (enExample) |
| JP (1) | JP2008519810A (enExample) |
| KR (1) | KR20070085470A (enExample) |
| CN (2) | CN101056641A (enExample) |
| AR (1) | AR053780A1 (enExample) |
| AT (1) | ATE439843T1 (enExample) |
| AU (1) | AU2005303778B2 (enExample) |
| BR (1) | BRPI0517818A2 (enExample) |
| CA (1) | CA2587283C (enExample) |
| CY (1) | CY1110538T1 (enExample) |
| DE (1) | DE602005016141D1 (enExample) |
| DK (1) | DK1814555T3 (enExample) |
| ES (1) | ES2329815T3 (enExample) |
| HR (1) | HRP20090513T1 (enExample) |
| IL (1) | IL182767A (enExample) |
| MX (1) | MX2007005827A (enExample) |
| MY (1) | MY144089A (enExample) |
| NO (1) | NO20072285L (enExample) |
| NZ (1) | NZ554858A (enExample) |
| PE (1) | PE20061051A1 (enExample) |
| PL (1) | PL1814555T3 (enExample) |
| PT (1) | PT1814555E (enExample) |
| RS (1) | RS51138B (enExample) |
| RU (1) | RU2396957C2 (enExample) |
| SI (1) | SI1814555T1 (enExample) |
| TW (1) | TW200631584A (enExample) |
| UA (1) | UA88655C2 (enExample) |
| WO (1) | WO2006051111A1 (enExample) |
| ZA (1) | ZA200703884B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007002174A2 (en) * | 2005-06-27 | 2007-01-04 | N.V. Organon. | A method of treatment of hormone depletion induced vasomotor symptoms |
| US20070129611A1 (en) * | 2005-12-06 | 2007-06-07 | University Of North Texas Health Science Center At Fort Worth | System, Method and Apparatus for Assessing Menopausal or Post-Hysterectomy Symptoms |
| EP1993556A1 (en) * | 2006-03-06 | 2008-11-26 | N.V. Organon | An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms |
| AU2007324467A1 (en) * | 2006-11-22 | 2008-05-29 | N.V. Organon | Vaginal delivery system for mirtazapine |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
| JP2009018992A (ja) | 2007-07-10 | 2009-01-29 | Sumitomo Chemical Co Ltd | 光学活性ミルタザピンの製造方法 |
| US8420624B2 (en) | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
| JP6876003B2 (ja) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置 |
| KR102608479B1 (ko) * | 2017-05-25 | 2023-12-01 | 글리테크 엘엘씨. | Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법 |
| WO2021167579A1 (ru) | 2020-02-19 | 2021-08-26 | Иван УЛИНИЧ | Универсальное устройство для тепловой обработки пищевых продуктов |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| US4515792A (en) * | 1982-09-30 | 1985-05-07 | Ciba-Geigy Corporation | Tetracyclic heterocycles and antidepressant compositions thereof |
| JPH1187727A (ja) * | 1997-09-12 | 1999-03-30 | Mitsubishi Electric Corp | 半導体装置 |
| ES2212550T3 (es) * | 1998-04-02 | 2004-07-16 | Akzo Nobel N.V. | Solucion oral liquida que comprende el antidepresor mirtazapina. |
| RU2195951C1 (ru) * | 2001-08-20 | 2003-01-10 | Общество с ограниченной ответственностью "Лаборатория "Ирис" | Средство для лечения климактерических расстройств |
-
2005
- 2005-11-10 TW TW094139442A patent/TW200631584A/zh unknown
- 2005-11-14 PE PE2005001334A patent/PE20061051A1/es not_active Application Discontinuation
- 2005-11-14 EP EP05808013A patent/EP1814555B1/en not_active Expired - Lifetime
- 2005-11-14 PL PL05808013T patent/PL1814555T3/pl unknown
- 2005-11-14 RS RSP-2009/0504A patent/RS51138B/sr unknown
- 2005-11-14 BR BRPI0517818-5A patent/BRPI0517818A2/pt not_active IP Right Cessation
- 2005-11-14 AR ARP050104768A patent/AR053780A1/es unknown
- 2005-11-14 JP JP2007540655A patent/JP2008519810A/ja active Pending
- 2005-11-14 PT PT05808013T patent/PT1814555E/pt unknown
- 2005-11-14 AU AU2005303778A patent/AU2005303778B2/en not_active Expired
- 2005-11-14 DK DK05808013T patent/DK1814555T3/da active
- 2005-11-14 AT AT05808013T patent/ATE439843T1/de active
- 2005-11-14 WO PCT/EP2005/055947 patent/WO2006051111A1/en not_active Ceased
- 2005-11-14 KR KR1020077011981A patent/KR20070085470A/ko not_active Ceased
- 2005-11-14 CN CNA200580038949XA patent/CN101056641A/zh active Pending
- 2005-11-14 CN CN2012102639294A patent/CN102772414A/zh active Pending
- 2005-11-14 MY MYPI20055321A patent/MY144089A/en unknown
- 2005-11-14 CA CA2587283A patent/CA2587283C/en not_active Expired - Fee Related
- 2005-11-14 MX MX2007005827A patent/MX2007005827A/es active IP Right Grant
- 2005-11-14 DE DE602005016141T patent/DE602005016141D1/de not_active Expired - Lifetime
- 2005-11-14 RU RU2007122391/14A patent/RU2396957C2/ru not_active IP Right Cessation
- 2005-11-14 UA UAA200705135A patent/UA88655C2/ru unknown
- 2005-11-14 NZ NZ554858A patent/NZ554858A/en not_active IP Right Cessation
- 2005-11-14 ES ES05808013T patent/ES2329815T3/es not_active Expired - Lifetime
- 2005-11-14 SI SI200530802T patent/SI1814555T1/sl unknown
- 2005-11-14 HR HR20090513T patent/HRP20090513T1/xx unknown
- 2005-11-14 US US11/667,579 patent/US20070265245A1/en not_active Abandoned
-
2007
- 2007-04-23 IL IL182767A patent/IL182767A/en not_active IP Right Cessation
- 2007-04-30 NO NO20072285A patent/NO20072285L/no not_active Application Discontinuation
- 2007-05-14 ZA ZA200703884A patent/ZA200703884B/xx unknown
-
2009
- 2009-10-12 CY CY20091101044T patent/CY1110538T1/el unknown
-
2010
- 2010-07-01 US US12/828,720 patent/US20100267694A1/en not_active Abandoned
-
2012
- 2012-08-09 US US13/570,481 patent/US20120302552A1/en not_active Abandoned
-
2013
- 2013-04-05 US US13/857,445 patent/US20130225559A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120302552A1 (en) | S-mirtazapine for the treatment of hot flush | |
| TWI330083B (en) | Methods for treating or preventing symptoms of hormonal variations | |
| JP3194734B2 (ja) | 迅速作用性選択的セロトニン再摂取阻害剤を用いた性的不全の処置方法 | |
| JPH10502644A (ja) | 免疫機能の調整方法 | |
| EA002554B1 (ru) | Применение кабэрголина при лечении синдрома усталых ног | |
| RU2012128109A (ru) | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) | |
| KR100425045B1 (ko) | 약물중독의치료를위한멜라토닌함유약학적조성물 | |
| KR100367792B1 (ko) | 테트라하이드로벤즈[cd]인돌-6-카복스아미드를 포함하는 성기능부전 치료용 약제 | |
| US20040092519A1 (en) | New treatment for hot flashes | |
| AU2020206399B2 (en) | Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain | |
| NZ544018A (en) | Asenapine for the treatment of schizophrenia in an overweight patient or a patient at risk for becoming overweight. | |
| HK1104235B (en) | S-mirtazapine for the treatment of hot flush | |
| CN114028374A (zh) | 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途 | |
| Mukand et al. | Olanzapine for the treatment of hemiballismus: A case report | |
| WO2017017511A1 (en) | Modified release formulation for treating premature ejaculation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |